CL2023000631A1 - Mutante de il-2 y aplicación de este - Google Patents

Mutante de il-2 y aplicación de este

Info

Publication number
CL2023000631A1
CL2023000631A1 CL2023000631A CL2023000631A CL2023000631A1 CL 2023000631 A1 CL2023000631 A1 CL 2023000631A1 CL 2023000631 A CL2023000631 A CL 2023000631A CL 2023000631 A CL2023000631 A CL 2023000631A CL 2023000631 A1 CL2023000631 A1 CL 2023000631A1
Authority
CL
Chile
Prior art keywords
mutants
methods
present disclosure
fusion proteins
unmodified
Prior art date
Application number
CL2023000631A
Other languages
English (en)
Inventor
Hu Yingying
Cao Zhuoxiao
Tang Renhong
Ge Hu
Fu Yayuan
Ren Jinsheng
Original Assignee
Shandong Simcere Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Simcere Biopharmaceutical Co Ltd filed Critical Shandong Simcere Biopharmaceutical Co Ltd
Publication of CL2023000631A1 publication Critical patent/CL2023000631A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente divulgación describe mutantes de IL-2 y usos de estos. Más específicamente, la divulgación proporciona mutantes de IL-2 y proteínas de fusión correspondientes, conjugados, fragmentos de ácido nucleico, vectores, células hospedadoras, métodos para preparar los mutantes o proteínas de fusión, mutantes de IL-2 o proteínas de fusión que se preparan de acuerdo con los métodos, composiciones farmacéuticas, usos farmacéuticos, métodos para tratar enfermedades y métodos para estimular preferentemente los linfocitos T reguladores. En comparación con la IL-2 no modificada, los mutantes de IL-2 de la presente divulgación tienen valores de Tm más altos y una estabilidad mejorada; como alternativa, los mutantes de IL-2 de la presente divulgación tienen un mayor rendimiento o una actividad de unión modificada a los complejos IL-2RBY en comparación con la IL-2 no modificada.
CL2023000631A 2020-09-04 2023-03-03 Mutante de il-2 y aplicación de este CL2023000631A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010918842 2020-09-04
CN202110932286 2021-08-13

Publications (1)

Publication Number Publication Date
CL2023000631A1 true CL2023000631A1 (es) 2023-10-13

Family

ID=80490673

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000631A CL2023000631A1 (es) 2020-09-04 2023-03-03 Mutante de il-2 y aplicación de este

Country Status (15)

Country Link
US (1) US20230265148A1 (es)
EP (1) EP4209503A1 (es)
JP (1) JP2023540761A (es)
KR (1) KR20230061490A (es)
CN (1) CN116323653A (es)
AU (1) AU2021338393A1 (es)
BR (1) BR112023004040A2 (es)
CA (1) CA3191260A1 (es)
CL (1) CL2023000631A1 (es)
IL (1) IL301027A (es)
MX (1) MX2023002648A (es)
PE (1) PE20240123A1 (es)
TW (1) TW202214677A (es)
WO (1) WO2022048640A1 (es)
ZA (1) ZA202304098B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023165553A1 (zh) * 2022-03-03 2023-09-07 海南先声药业有限公司 IL2突变体-抗体Fc嵌段融合蛋白的药物组合物及其应用
US20240076343A1 (en) * 2022-06-16 2024-03-07 Cephalon Llc Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
WO2023241653A1 (zh) * 2022-06-17 2023-12-21 舒泰神（北京）生物制药股份有限公司 白介素-2(il-2)突变体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23734A1 (es) * 2009-11-27 2011-11-15 Centro Inmunologia Molecular Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
CN104231068A (zh) * 2014-01-27 2014-12-24 苏州发士达生物科技有限公司 人白细胞介素ii突变体及其应用
CN113166220A (zh) * 2018-03-09 2021-07-23 奥美药业有限公司 创新细胞因子前药

Also Published As

Publication number Publication date
BR112023004040A2 (pt) 2023-04-04
EP4209503A1 (en) 2023-07-12
CA3191260A1 (en) 2022-03-10
KR20230061490A (ko) 2023-05-08
MX2023002648A (es) 2023-04-05
CN116323653A (zh) 2023-06-23
IL301027A (en) 2023-05-01
JP2023540761A (ja) 2023-09-26
WO2022048640A1 (zh) 2022-03-10
ZA202304098B (en) 2023-09-27
PE20240123A1 (es) 2024-01-22
US20230265148A1 (en) 2023-08-24
TW202214677A (zh) 2022-04-16
AU2021338393A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
CL2023000631A1 (es) Mutante de il-2 y aplicación de este
JP7282834B2 (ja) 共通ネオ抗原
CL2020000252A1 (es) Muteínas de interleucina 21 y métodos de tratamiento.
Lukashev et al. Viral vectors for gene therapy: current state and clinical perspectives
Zuris et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
ES2874077T3 (es) Métodos y compuestos mejorados para eliminar respuestas inmunitarias a agentes terapéuticos
BR112021022874A2 (pt) Proteínas de ligação epcam e métodos de uso
BR112022016550A2 (pt) Proteínas de ligação a flt3 e métodos de uso
CL2022000664A1 (es) Proteínas de fijación multiespecíficas para tratamiento contra el cáncer
JP2018525437A5 (es)
AU2016277883A8 (en) PD-1-CD28 fusion proteins and their use in medicine
BR112022008744A2 (pt) Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
CY1126148T1 (el) Καινοτομος χιμαιρικη πρωτεϊνη ειδικη για τις cd137 και pd-l1
MX2021010039A (es) Novedosas proteinas de fusion especificas para cd137 y gpc3.
BR112022007128A2 (pt) Ligação de proteínas nkg2d, cd16 e flt3
MX2022004086A (es) Anticuerpos anti inmunorreceptor de celulas t con dominios de inmunoglobulina y motivo inhibidor basado en tirosina de inmunorreceptor (tigit) y sus usos.
BR112022008201A2 (pt) Degradação de proteínas de superfície usando agente de ligação biespecífico
BR112022008321A2 (pt) Polipeptídeos isolados, polipeptídeo, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos para produzir um polipeptídeo, para tratar câncer, para tratar uma doença neurológica ou neurodegenerativa, para repolarizar células supressoras, para repolarizar macrófagos de tumor e para ativar células mieloides em um sujeito e composições farmacêuticas
WO2023049636A3 (en) Cancer therapy compositions and uses thereof
EA201992692A1 (ru) Нацеленные на msln триспецифические белки и способы применения
EA202090431A1 (ru) Мутеины интерлейкина-21 и способы лечения
Kumar et al. Novel therapy for oral cancer-Gene therapy an update